1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- Kaken Downwardly Revises Business Forecasts for FY2001
October 15, 2001
- 36 New Products Receive Regulatory Approval
October 15, 2001
- NEW PRODUCTS NEWS IN BRIEF
October 15, 2001
- Use of Domestic Cow-Derived Raw Materials in Drugs Banned
October 15, 2001
- OTC NEWS IN BRIEF
October 15, 2001
- Switch to Materials from BSE-free Countries Considered by Makers
October 15, 2001
- Cooperation of Medical Institutions Essential for Immediate PMS
October 15, 2001
- Medical Professionals Asked For Cooperation with Immediate PMS
October 15, 2001
- Bungyo Rate Increases to 42.8% in June
October 15, 2001
- Cooperation for Immediate PMS Urged by SD Director
October 15, 2001
- WORLD NEWS IN BRIEF
October 15, 2001
- Korosho to Reduce Number of Hospital Beds by Shortening Hospital Stay
October 15, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 15, 2001
- REGULATORY NEWS IN BRIEF
October 15, 2001
- Etiology of Alzheimer Disease Should Be Clarified by 2013
October 15, 2001
- Mr Nagayama Calls For Drug Prices Proportional to Value
October 15, 2001
- Inhalant Steroids Are Effective for Asthma: Yomiuri, GSK Forum
October 15, 2001
- Bayer to File NDA for Vardenafil by Year-end in Japan
October 15, 2001
- Sysmex Aims at \72 Bil. Sales, 7.5% ROE in FY2004
October 15, 2001
- Ohmori, Sanuki, Baikado Tie Up to Cover Entire Shikoku Market
October 15, 2001
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…